RecruitingNCT04180930

An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample

Psychometric Evaluation of the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Symptom Scale Interview for DSM-5 (PSSI-5) in an Active Duty and Military Veteran Sample


Sponsor

U.S. Army Medical Research and Development Command

Enrollment

950 participants

Start Date

Apr 15, 2019

Study Type

OBSERVATIONAL

Conditions

Summary

Given the high prevalence of post-traumatic stress disorder (PTSD) in veterans and active duty military, the focus of this research study is to test the reliability of two new PTSD assessments, the Clinician Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Symptom Scale Interview for DSM-5 (PSSI-5) and compare the results between the two new assessments and the previous "gold standard", the Clinician Administered PTSD Scale for DSM-IV (CAPS-IV). Biomarkers believed to be related to PTSD (e.g., biofluid biomarkers, cognitive and physiological markers, and neural activity as measured by EEG) will be collected to inform targeted interventions in specific groups of patients and other large-scale biomarker discovery efforts in the field. Participants will be 950 male and female active duty military and veterans ages 18 or older who have been exposed to at least one traumatic event.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Male or female active duty personnel or military veterans, 18 years of age or older
  • Competent to give informed consent
  • Have experienced any Criterion A qualifying traumatic event as defined by the Life Events Checklist for DSM-5 (LEC-5)
  • Score a 3 or above on the Primary Care-Post Traumatic Stress Disorder Screen (PC-PTSD-5)

Exclusion Criteria5

  • Current suicidal or homicidal ideation with a plan, and substance use disorder requiring detoxification currently or in the past month as assessed using the SCID and Suicidal Ideation/Homicidal Ideation screening tool (SI/HI screen)
  • Assessment using CAPS or PSSI in the previous 1 year
  • Currently receiving psychotherapy or counseling for PTSD
  • Moderate to sever cognitive impairment as measured by the Montreal Cognitive Assessment (MoCA)
  • Meet criteria for unmedicated Bipolar I, Bipolar II, Schizophrenia, or other psychotic disorders in the last month

Interventions

DIAGNOSTIC_TESTCAPS-5

Clinician Administered PTSD Scale for DMS-5

DIAGNOSTIC_TESTPSSI-5

PTSD Symptom Scale Interview for DSM-5

DIAGNOSTIC_TESTCAPS-IV

Clinician Administered PTSD Scale for DSM-IV


Locations(3)

Tripler Army Medical Center

Honolulu, Hawaii, United States

Cincinnati VA Medical Center - Trauma Recovery Center

Fort Thomas, Kentucky, United States

Walter Reed National Military Medical Center

Bethesda, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04180930


Related Trials